LV11731A - Parathormona lidzeklis - Google Patents

Parathormona lidzeklis

Info

Publication number: LV11731A
Authority: LV; Latvia
Prior art keywords: parathyroid hormone; excipient; buffering agent; reconstitution; vials
Prior art date: 1993-12-23

Application number

LV960283A

Other languages

English (en)

Other versions

LV11731B (en

Inventor

Josephus Johannes Mar Holthuis

Albert Mekking

Alwinus Antonius Voetman

Original Assignee

Allelix Biopharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-23

Filing date

1996-07-19

Publication date

1997-04-20

1996-07-19 Application filed by Allelix Biopharma filed Critical Allelix Biopharma

1997-04-20 Publication of LV11731A publication Critical patent/LV11731A/lv

1997-08-20 Publication of LV11731B publication Critical patent/LV11731B/en

Links

239000000199 parathyroid hormone Substances 0.000 title abstract 3
108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
229960001319 parathyroid hormone Drugs 0.000 title abstract 2
239000006172 buffering agent Substances 0.000 abstract 2
239000000546 pharmaceutical excipient Substances 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract 1
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
102000058004 human PTH Human genes 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

LVP-96-283A 1993-12-23 1996-07-19 Parathyroid hormone formulation LV11731B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/172,206 US5496801A (en)	1993-12-23	1993-12-23	Parathyroid hormone formulation
PCT/CA1994/000693 WO1995017207A1 (en)	1993-12-23	1994-12-16	Parathyroid hormone formulation

Publications (2)

Publication Number	Publication Date
LV11731A true LV11731A (lv)	1997-04-20
LV11731B LV11731B (en)	1997-08-20

Family

ID=22626763

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-96-283A LV11731B (en)	1993-12-23	1996-07-19	Parathyroid hormone formulation

Country Status (22)

Country	Link
US (1)	US5496801A (lv)
EP (2)	EP0735896B1 (lv)
JP (1)	JP3065662B2 (lv)
KR (1)	KR100398461B1 (lv)
CN (1)	CN1116897C (lv)
AT (1)	ATE374621T1 (lv)
AU (1)	AU681737B2 (lv)
BR (1)	BR9408398A (lv)
CA (1)	CA2179207C (lv)
CZ (1)	CZ184296A3 (lv)
DE (1)	DE69435033T2 (lv)
DK (1)	DK0735896T3 (lv)
ES (1)	ES2293637T3 (lv)
FI (1)	FI120291B (lv)
HU (1)	HUT74381A (lv)
LV (1)	LV11731B (lv)
NO (1)	NO324905B1 (lv)
NZ (1)	NZ277463A (lv)
PL (1)	PL315158A1 (lv)
PT (1)	PT735896E (lv)
SK (1)	SK82896A3 (lv)
WO (1)	WO1995017207A1 (lv)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3095092A (en) *	1991-12-09	1993-07-19	Asahi Kasei Kogyo Kabushiki Kaisha	Stabilized parathyroid hormone composition
US6509316B2 (en) *	1995-03-07	2003-01-21	George Washington University	Pharmaceutical compositions, methods, and kits for treatment and diagnosis of lung cancer
SE9702401D0 (sv) *	1997-06-19	1997-06-19	Astra Ab	Pharmaceutical use
AU8356198A (en) *	1997-07-22	1999-02-16	Chugai Seiyaku Kabushiki Kaisha	Dental remedies containing pth
US6770623B1 (en) *	1997-12-09	2004-08-03	Eli Lilly And Company	Stabilized teriparatide solutions
ZA9811127B (en) *	1997-12-09	2000-07-11	Lilly Co Eli	Stabilized teriparatide solutions.
BR9813740A (pt) *	1997-12-18	2000-10-10	Lilly Co Eli	Teriparatìdeo cristalino
SE9801495D0 (sv) *	1998-04-28	1998-04-28	Astra Ab	Protein formulationa
AU1447600A (en) *	1998-10-22	2000-05-08	Thomas J. Gardella	Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
AU4217299A (en) *	1998-11-30	2000-06-19	General Hospital Corporation, The	Pth1r and pth3r receptors, methods and uses thereof
US6689566B1 (en)	1999-01-14	2004-02-10	Scantibodies Laboratory, Inc.	Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) *	1999-01-14	2010-10-26	Scantibodies Laboratory, Inc.	Methods, kits and antibodies for detecting parathyroid hormone
US20080108086A1 (en) *	1999-06-02	2008-05-08	Cantor Thomas L	Parathyroid hormone antagonists and uses thereof
US7893021B2 (en) *	1999-06-02	2011-02-22	Scantibodies Laboratory, Inc.	Parathyroid hormone antagonists and uses thereof
ES2300268T3 (es) *	1999-07-12	2008-06-16	Sandoz Ag	Formulaciones de las hormonas de crecimiento.
AU7734800A (en) *	1999-09-29	2001-04-30	General Hospital Corporation, The	Polypeptide derivatives of parathyroid hormone (pth)
EP1251867A4 (en)	2000-02-04	2004-12-08	Unigene Lab Inc	NASAL CALCITON INFORMATION
WO2001087322A2 (en) *	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
US6387711B1 (en) *	2000-08-11	2002-05-14	Quest Diagnostics Investments Incorporated	Liquid intact parathyroid hormone (PTH) standards
US6905886B2 (en) *	2000-08-11	2005-06-14	Quest Diagnostics Investments Incorporated	Preservative solutions
US7226442B2 (en) *	2000-10-10	2007-06-05	Microchips, Inc.	Microchip reservoir devices using wireless transmission of power and data
AR038658A1 (es) *	2001-06-15	2005-01-26	Novartis Ag	Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
KR100491737B1 (ko) *	2001-07-20	2005-05-27	주식회사 한국아이템개발	공기 정화 기능의 모기 퇴치기
CA2454275C (en)	2001-07-23	2012-10-23	The General Hospital Corporation	Conformationally constrained parathyroid hormone (pth) analogs
WO2004022033A1 (en) *	2002-09-04	2004-03-18	Microchips, Inc.	Method and device for the controlled delivery of parathyroid hormone
US20040067526A1 (en) *	2002-10-03	2004-04-08	Cantor Thomas L.	Methods for diagnosing and guiding treatment of bone turnover disease
US7795220B2 (en) *	2003-03-19	2010-09-14	The General Hospital Corporation	Conformationally constrained parathyroid hormones with alpha-helix stabilizers
MXPA06000281A (es) *	2003-06-30	2006-07-03	Johnson & Johnson	Formulaciones para microproyecciones revestidas que contienen contraiones no volatiles.
KR100540659B1 (ko) *	2003-07-02	2006-01-10	삼성전자주식회사	이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체
WO2005014034A1 (en) *	2003-07-14	2005-02-17	Nps Allelix Corp.	Stabilized formulation of parathyroid hormone
WO2005009358A2 (en)	2003-07-17	2005-02-03	The General Hospital Corporation	Conformationally constrained parathyroid hormone (pth) analogs
US7459276B2 (en) *	2003-09-29	2008-12-02	Scantibodies Laboratory, Inc.	Methods and controls for monitoring assay quality and accuracy in parathyroid hormone measurement
US20050119183A1 (en) *	2003-11-12	2005-06-02	Nps Allelix Corp.	Method for treating bone loss using parathyroid hormone
BRPI0416042A (pt) *	2003-11-13	2007-01-02	Alza Corp	composição e aparelho para suprimento transdérmico
CN100406059C (zh) *	2004-04-30	2008-07-30	陈新梅	甲状旁腺激素的新用途
MXPA06013168A (es) *	2004-05-13	2007-05-15	Johnson & Johnson	Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US7541140B2 (en) *	2004-06-03	2009-06-02	Scantibodies Laboratory, Inc.	Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
CA2595457A1 (en) *	2005-01-25	2006-08-03	Microchips, Inc.	Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) *	2005-01-25	2008-03-27	Microchips, Inc.	Method and implantable device with reservoir array for pre-clinical in vivo testing
KR100700869B1 (ko)	2005-06-03	2007-03-29	재단법인 목암생명공학연구소	Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CN101355959B (zh) *	2005-11-10	2013-02-27	密歇根理工大学管理委员会	黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
EP2054077A4 (en) *	2006-08-04	2010-10-13	Gen Hospital Corp	POLYPEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH)
EP1961765A1 (en) *	2006-12-08	2008-08-27	Zealand Pharma A/S	Truncated PTH peptides with a cyclic conformation
AU2008282805B2 (en)	2007-08-01	2014-05-01	Chugai Pharmaceutical Co., Ltd.	Screening methods using G-protein coupled receptors and related compositions
US8298789B2 (en) *	2007-08-09	2012-10-30	Usv Limited	Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34)
JP2009091363A (ja) *	2008-11-21	2009-04-30	Asahi Kasei Pharma Kk	Ｐｔｈの安定化水溶液注射剤
EP2509996A1 (en)	2009-12-07	2012-10-17	Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2011143406A2 (en)	2010-05-13	2011-11-17	The General Hospital Corporation	Parathyroid hormone analogs and uses thereof
EP2683364B1 (en) *	2011-03-10	2017-01-18	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of peptide drugs
WO2012169435A1 (ja) *	2011-06-07	2012-12-13	旭化成ファーマ株式会社	高純度ｐｔｈ含有凍結乾燥製剤およびその製造方法
WO2014151381A1 (en)	2013-03-15	2014-09-25	Psivida Us, Inc.	Bioerodible silicon-based compositions for delivery of therapeutic agents
CN103301058A (zh) *	2013-06-17	2013-09-18	深圳翰宇药业股份有限公司	一种特立帕肽注射用组合物及其制备方法和制剂
JP7399382B2 (ja) *	2018-07-30	2023-12-18	武田薬品工業株式会社	組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
JP2023500472A (ja) *	2019-10-28	2023-01-06	ブリリアン・ファーマ・インコーポレイテッド	経口乾燥溶液及び懸濁物のための医薬品単位用量システム
CN110917150A (zh) *	2019-12-31	2020-03-27	北京博康健基因科技有限公司	一种pth冻干制剂及其制备方法
US20230190880A1 (en) *	2020-03-30	2023-06-22	Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd.	Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3768177A (en) *	1972-08-02	1973-10-30	R Thomas	Educational device
US4105602A (en) *	1975-02-10	1978-08-08	Armour Pharmaceutical Company	Synthesis of peptides with parathyroid hormone activity
US4016314A (en) *	1975-06-26	1977-04-05	Hallco Inc.	Embroidered fruit bowl wall hanging and kit for making same
US4199060A (en) *	1978-07-20	1980-04-22	Howard Hardware Products, Inc.	Lock installation kit
US4424278A (en) *	1981-11-16	1984-01-03	Research Corporation	Cancer detection procedure using an acyl carrier protein
JPS61267528A (ja) *	1984-11-26	1986-11-27	Yamanouchi Pharmaceut Co Ltd	吸収促進剤を含有するカルシトニン経鼻剤
US4812311A (en) *	1984-12-21	1989-03-14	The Procter & Gamble Company	Kit for use in the treatment of osteoporosis
IL78342A (en) *	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
JPS6360940A (ja) *	1986-09-01	1988-03-17	Toyo Jozo Co Ltd	白内障の予防または治療剤
US4833125A (en) *	1986-12-05	1989-05-23	The General Hospital Corporation	Method of increasing bone mass
US5059587A (en) *	1987-08-03	1991-10-22	Toyo Jozo Company, Ltd.	Physiologically active peptide composition for nasal administration
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
DE3935738A1 (de) *	1989-10-27	1991-05-08	Forssmann Wolf Georg	Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) *	1990-09-20	1990-10-31	Sandoz Ltd	Improvements in or relating to organic compounds
JP3090353B2 (ja) *	1991-09-17	2000-09-18	旭化成工業株式会社	パラチロイドホルモン類含有経鼻投与用乳剤
AU3095092A (en) *	1991-12-09	1993-07-19	Asahi Kasei Kogyo Kabushiki Kaisha	Stabilized parathyroid hormone composition
JPH07502507A (ja) *	1991-12-17	1995-03-16	プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド	ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
IT1255723B (it) *	1992-10-09	1995-11-13		Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione

1993
- 1993-12-23 US US08/172,206 patent/US5496801A/en not_active Expired - Lifetime
1994
- 1994-12-16 WO PCT/CA1994/000693 patent/WO1995017207A1/en not_active Ceased
- 1994-12-16 SK SK828-96A patent/SK82896A3/sk unknown
- 1994-12-16 AU AU12698/95A patent/AU681737B2/en not_active Expired
- 1994-12-16 CZ CZ961842A patent/CZ184296A3/cs unknown
- 1994-12-16 CA CA002179207A patent/CA2179207C/en not_active Expired - Lifetime
- 1994-12-16 PL PL94315158A patent/PL315158A1/xx unknown
- 1994-12-16 EP EP95903732A patent/EP0735896B1/en not_active Expired - Lifetime
- 1994-12-16 HU HU9601721A patent/HUT74381A/hu unknown
- 1994-12-16 NZ NZ277463A patent/NZ277463A/en not_active IP Right Cessation
- 1994-12-16 ES ES95903732T patent/ES2293637T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP07019169A patent/EP1880732A1/en not_active Withdrawn
- 1994-12-16 BR BR9408398A patent/BR9408398A/pt not_active Application Discontinuation
- 1994-12-16 PT PT95903732T patent/PT735896E/pt unknown
- 1994-12-16 CN CN94194608A patent/CN1116897C/zh not_active Expired - Lifetime
- 1994-12-16 DE DE69435033T patent/DE69435033T2/de not_active Expired - Lifetime
- 1994-12-16 KR KR1019960703288A patent/KR100398461B1/ko not_active Expired - Lifetime
- 1994-12-16 DK DK95903732T patent/DK0735896T3/da active
- 1994-12-16 JP JP7517064A patent/JP3065662B2/ja not_active Expired - Lifetime
- 1994-12-16 AT AT95903732T patent/ATE374621T1/de active
1996
- 1996-06-20 NO NO19962634A patent/NO324905B1/no not_active IP Right Cessation
- 1996-06-20 FI FI962593A patent/FI120291B/fi not_active IP Right Cessation
- 1996-07-19 LV LVP-96-283A patent/LV11731B/en unknown

Also Published As

Publication number	Publication date
CN1116897C (zh)	2003-08-06
PT735896E (pt)	2007-12-07
EP0735896A1 (en)	1996-10-09
KR100398461B1 (ko)	2004-03-20
SK82896A3 (en)	1997-01-08
NO962634D0 (no)	1996-06-20
JP3065662B2 (ja)	2000-07-17
JPH09506869A (ja)	1997-07-08
FI120291B (fi)	2009-09-15
LV11731B (en)	1997-08-20
DE69435033T2 (de)	2008-05-29
FI962593L (fi)	1996-08-19
ATE374621T1 (de)	2007-10-15
CN1142772A (zh)	1997-02-12
HU9601721D0 (en)	1996-08-28
WO1995017207A1 (en)	1995-06-29
PL315158A1 (en)	1996-10-14
HUT74381A (en)	1996-12-30
EP0735896B1 (en)	2007-10-03
NO962634L (no)	1996-06-20
AU681737B2 (en)	1997-09-04
CZ184296A3 (en)	1997-01-15
BR9408398A (pt)	1997-08-12
AU1269895A (en)	1995-07-10
ES2293637T3 (es)	2008-03-16
NO324905B1 (no)	2007-12-27
CA2179207A1 (en)	1995-06-29
US5496801A (en)	1996-03-05
HK1010336A1 (en)	1999-06-17
NZ277463A (en)	1997-03-24
EP1880732A1 (en)	2008-01-23
DK0735896T3 (da)	2008-02-04
FI962593A0 (fi)	1996-06-20
CA2179207C (en)	2000-11-14
DE69435033D1 (de)	2007-11-15

Publication	Publication Date	Title
LV11731A (lv)	1997-04-20	Parathormona lidzeklis
EP0619119A4 (en)	1995-07-12	COMPOSITION BASED ON STABILIZED PARATHYROIDIAN HORMONE.
ES2055845T3 (es)	1994-09-01	Composicion farmaceutica para el tratamiento de la osteoporosis.
UA72884C2 (uk)	2005-05-16	Стабілізовані розчини паратирину
EP0607325A4 (en)	1996-11-06	Parathyroid hormone analogues substituted at aa?25,26,27 and use in osteoporosis treatment.
BR9402902A (pt)	1995-04-11	Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica.
DE3880421D1 (de)	1993-05-27	Pharmazeutische zubereitungen zur behandlung der psoriasis, psoriatischen arthritis, neurodermitis und enteritis regionalis crohn.
DE69434588D1 (de)	2006-02-02	Verzögerte Freigabe von Insulinotropin (GLP-1)
ZA886528B (en)	1989-05-30	Stabilised human protein preparations
AU5561686A (en)	1986-10-09	Method of increasing bone mass
DK0588539T3 (da)	1997-03-10	Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3
SE8504945L (sv)	1986-04-23	Farmaceutiska kompositioner innehallande antracyklinglykosider
NZ230280A (en)	1991-09-25	Pharmaceutical formulation containing an insulin derivative modified with a base, with an isoelectric point between 5.8 - 8.5, and with a zinc ion content of from 2mug - 200mug of zinc/iu
DK0582239T3 (da)	1999-12-06	Farmaceutisk og/eller kosmetisk formulering
HUT47436A (en)	1989-03-28	Process for stabilizing pharmaceutically active proteines in pharmaceutical compositions
DE69017690D1 (de)	1995-04-13	Pharmazeutische zusammensetzungen.
EP0656784A4 (en)	1997-06-04	PARATHYROID HORMONE FRAGMENTS AND ANALOGS.
IL92061A0 (en)	1990-07-12	Pharmaceutical compositions containing biologically active peptides and certain anions
HUT63575A (en)	1993-09-28	Stabilized pharmaceutical composition comprising the reduced form of non-glycosylated, recombinant human interleukin-2
AU4685389A (en)	1990-07-05	Pharmaceutical compositions and use thereof in the treatment of psoriasis
EP0419890A3 (en)	1991-05-29	Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
EP0265338A3 (en)	1989-04-05	Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them
EP0175323A3 (en)	1989-02-08	Biologically active peptides, processes for preparing them and pharmaceutical compositions
IE883402L (en)	1989-05-13	Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
JPS5223586A (en)	1977-02-22	Carrier for fixing physiologically active material